Abstract: Diphencyprone has been reported as a local immunotherapy for cutaneous melanoma metastases. We aim to report cases of melanoma patients treated with diphencyprone in a single Brazilian institution and highlight their outcomes. Since 2012, we have treated 16 melanoma patients with cutaneous metastases with topical diphencyprone. To date, we have had 37.5% of complete response, 25% of partial responses, and 31.25% patients without any response. Treatment was well tolerated and local toxicity was easily controlled. We believe topical diphencyprone is a feasible treatment that can be another option for treating melanoma patients, especially in cases of in-transit or extensive disease. Keywords: Melanoma; Neoplasm metastasis; Therapeutics Diphencyprone (DPCP) is a potent contact sensitizer that has most frequently been used as immunotherapy for cutaneous warts and alopecia areata.
Diphencyprone (DPCP) is a potent contact sensitizer that has most frequently been used as immunotherapy for cutaneous warts and alopecia areata. 1, 2 There are reports of DPCP combined with oral cimetidine or dacarbazine and radiotherapy to treat cutaneous melanoma metastases. 3, 4 Its mechanism is still unclear. Nevertheless, there are several reports in the literature presenting DPCP as an option for melanoma patients with in-transit metastases or patients with extensive or bulky disease.
1,5
The largest case series comes from Australia, with 50 melanoma patients treated with DPCP. 6 The initial experiences of both a
British and a Canadian center were also reported with very similar results.
5,7
The objective of this study is to report cases of melanoma patients treated with DPCP as a single topic agent in a single Brazilian institution, and to highlight their outcomes regarding tumor response.
After being informed about the potential risks and benefits of the treatment, all patients signed the informed written consent.
DPCP was first used in our institution in 2012, following the methodology previously reported in the literature. 1 Briefly, the patient is initially sensitized with a 2% solution of DPCP in acetone, which is applied to the arm or back, and held in contact by an occlusive dressing for 48 hours. If an eczematous reaction is seen, the patient is considered sensitized and waits for 10-14 days before starting receiving DPCP 0.005% in aqueous cream. DPCP 0.005% is then applied to the targeted melanoma lesions. The area is covered with a dressing that remains closed for 24 hours. This procedure is then repeated weekly with patient kept under observation. Whenever necessary, the concentration of DPCP is adjusted.
We performed post treatment biopsies in treated tumor areas and used standard parameters to process pathology specimens.
Haematoxilin & eosin (HE) slides were reviewed by experienced pathologists that further categorized the lesions into complete response (CR), partial response (PR), and no response (NR), according to the amount of residual tumor or presence of tissue inflammation.
Sixteen patients were treated with DPCP in the last 5 years (9 males, 7 females; mean age = 62.38, 21-87 years). All patients had previous diagnosis of invasive melanoma. In most cases, DPCP was used to treat in-transit disease or cutaneous metastasis. However, there were 2 cases of visceral metastasis.
Clinical follow-up examinations were performed monthly (or whenever necessary). Response evaluation was performed with biopsies in treated areas, usually after 3 months of treatment. To The most common side effect was local erythema, which was initially treated with skin moisturizers. We also needed to reduce DPCP concentration to 0.0025% in 3 patients. One patient needed systemic corticosteroids and 1 needed anti-histamine therapy. We observed no harm to patients who required these other medications.
Pathological assessment after treatment was very important. Although most patients still presented with cutaneous lesions, biopsies showed only pigment and melanophages ( Figure 1 ). This pattern was seen is all patients who showed CR or PR (Figure 2 ).
Some patients used DPCP before systemic treatments, and some used it simultaneously. We observed no interference of DPCP in the toxicity of these treatments, including patients who underwent immunotherapies. 
